Increase of adhesion molecules, fibrinogen, type‐1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: GH deficiency (GHD) is usually associated with a higher incidence of cardiovascular disease (CVD). The aim of this study was to establish whether patients with GHD, like those with CVD, show an increase in fibrinogen (FBG), type‐1 plasminogen activator inhibitor (PAI‐1), acute phase response proteins (APR), and soluble adhesion molecules. The effect of recombinant human GH (rhGH) replacement, on these parameters was also investigated. PATIENTS AND DESIGN: Concentrations of PAI‐1 antigen (Ag), adhesion molecules s E‐selectin, s P‐selectin, and intercellular adhesion molecule‐1 (s ICAM‐1), FBG and levels of APR orosomucoid (ORM), and ‘negative APR’ transferrin (TRF) were established in 11 panhypopituitary (PHP) patients (eight men and three women, age median 39.0 years, body mass index (BMI) 27.49 ± 3.89 kg/m 2) before and after 12‐month replacement with rhGH. Control values were obtained by examination of 33 healthy age and sex matched subjects (24 men and nine women with BMI 24.16 ± 1.99 kg/m 2). RESULTS: PHP patients had higher concentrations of ORM (0.80 ± 0.25, vs. 0.61 ± 0.20 g/l; P = 0.05), FBG (3.22 ± 0.48, vs. 2.57 ± 0.47 g/l; P = 0.001), PAI‐1 Ag (97.12 ± 33.23, vs. 44.11 ± 21.40 μg/l; P = 0.001), s E‐selectin (72.42 ± 28.35, vs. 42.80 ± 12.60 μg/l; P = 0.004), s P‐selectin (221.26 ± 75.12, vs. 104.79 ± 26.01 μg/l; P = 0.001) s ICAM‐1 (409.75 ± 137.78, vs. 228.10 ± 37.54 μg/l; P = 0.001), and lower levels of TRF (2.14 ± 0.40, vs. 2.76 ± 0.39 g/l; P = 0.001) than controls. After 12‐month rhGH replacement the patients showed an increase of TRF (2.64 ± 0.84 g/l, P = 0.037) and decrease of soluble adhesion molecules (s E‐selectin 57.98 ± 27.04 μg/l, P = 0.01, s P‐selectin 121.74 ± 50.42 μg/l, P = 0.007; and s ICAM‐1 279.95 ± 88.32 μg/l, P = 0.005), which then, similarly to the ORM (0.67 ± 0.12 g/l) and FBG level (2.82 ± 0.51 g/l), did not statistically differ from the values in the control group. CONCLUSION: rhGH replacement led to modulation of the ‘inflammatory response’ in panhypopituitary patients. This modulation occurred locally at vascular endothelium level where after rhGH replacement, s E‐selectin, s P‐selectin and s ICAM‐1 concentrations decreased, a similar effect as in the systemic inflammatory response, as was also apparent from the changes in acute phase response protein levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 10×
“The aim of this study was to establish whether patients with GHD, like those with CVD, show an increase in ®brinogen (FBG), type-1 plasminogen activator inhibitor (PAI-1), acute phase response proteins (APR), and soluble adhesion molecules.”
MethodInfluentialRidker, P. M., Hennekens, C. H., Roitman-Johnson, B., Stampfer, M. J., & Allen, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09032-6 · Cited by 1,229 · cited 2×
“…alpha-1-acid glycoprotein), and of soluble adhesion molecules E-selectin, P-selectin and ICAM-1 (intercellular adhesion molecule-1), increased levels of which are found in cardiovascular disease of atherosclerotic origin (Held et al., 1997; Ridker, 1997; Ridker et al., 1998; Lindberg et al., 1999).”
BackgroundIncreased mortality associated with growth hormone treatment in critically ill adults
Takala, J., Ruokonen, E., Webster, N. R., Nielsen, M. S., Zandstra, D. F., Vundelinckx, G., & Hinds, C. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411102 · Cited by 1,023
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
Markussis, V., Beshyah, S. A., Johnston, D. G., Fisher, C., Nicolaides, A. N., & Sharp, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)92892-j · Cited by 390
Samad, F., Uysal, K. T., Wiesbrock, S. M., Pandey, M., Hotamisligil, G. S., & Loskutoff, D. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6902 · Cited by 226
Cited by
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Mortality in adults with hypopituitarism: a systematic review and meta-analysis
Jasim, S., Alahdab, F., Ahmed, A. T., Tamhane, S., Prokop, L. J., Nippoldt, T. B., & Murad, M. H. (2017) · Endocrine · doi:10.1007/s12020-016-1159-3 · Cited by 112
Beauregard, C., Utz, A. L., Schaub, A. E., Nachtigall, L., Biller, B. M. K., Miller, K. K., & Klibanski, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2371 · Cited by 99
Murray, R. D., Wieringa, G., Lawrance, J. A., Adams, J. E., & Shalet, S. M. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03754.x · Cited by 24
Tanriverdi, F., Karaca, Z., Unluhizarci, K., & Kelestimur, F. (2014) · Endocrine · doi:10.1007/s12020-014-0276-0 · Cited by 20
Metadata
- Authors
- Kvasnička, J., Marek, J., Kvasnička, T., Weiss, V., Marková, M., Štìěpán, J., & Umlaufová, A.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2000-05-19
- Volume
- 52
- Issue
- 5
- Pages
- 543-548
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2013990444
- Cited by
- 53
- References
- 6
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increase of adhesion molecules, fibrinogen, type‐1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. https://app.cochat.ai/papers/10.1046/j.1365-2265.2000.01002.x
- The paper
- Kvasnička, J., Marek, J., Kvasnička, T., Weiss, V., Marková, M., Štìěpán, J., & Umlaufová, A. (2000). Increase of adhesion molecules, fibrinogen, type‐1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2000.01002.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.